Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 5,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Interventions: D-Mannose, Placebo; Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Covid-19
Interventions: Convalescent plasma transfusion; Biological
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: HIV, HIV Infections
Interventions: Stribild, ATV, Ritonavir, FTC/TDF, Stribild Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 86
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more

Conditions: Skin Infection
Interventions: Dalbavancin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Burns
Interventions: Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 3 Months and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 9
States / cities: Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more

Conditions: Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Interventions: vaginal cooling device; Device
Lead sponsor: Coologics, Inc; Industry
Eligibility: 22 Years to 49 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Jacksonville, Florida • Miami, Florida • Smyrna, Georgia + 7 more

Conditions: Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
Interventions: UB-421; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sexually Transmitted Infection, Gonorrhea Female, Chlamydia Females
Interventions: Cepheid Xpert CT/NG Rapid Turnaround Test, Polymerase chain reaction (PCR); Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postoperative Complications, Surgical Wound Infection, Surgical Wound Dehiscence
Interventions: acupuncture, sham acupuncture; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid Use Disorder, Injection Related Infections, Stimulant Use Disorder
Interventions: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC); Behavioral
Lead sponsor: Elana Rosenthal; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more

Conditions: Covid19, Aspergillosis, Fungal Infection
Interventions: Observation to monitor patients for these infections; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Infection
Interventions: Omiganan 1% gel, Povidone-Iodine 10%; Drug
Lead sponsor: Cadence Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 1,859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 36
States / cities: Mobile, Alabama • Phoenix, Arizona • Arcadia, California + 33 more

Conditions: Surgical Site Infection
Interventions: Implementation of the AO Trauma SSI Prevention Bundle; Behavioral
Lead sponsor: AO Clinical Investigation and Publishing Documentation; Other
Eligibility: 18 Years to 100 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Los Angeles, California • Lexington, Kentucky • Worcester, Massachusetts + 5 more

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, ALVAC MART-1 Vaccine, aldesleukin, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A, Saline placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Huntsville, Alabama • Jacksonville, Florida • Miami, Florida + 7 more

Conditions: Respiratory Syncytial Virus Infection Prevention
Interventions: Ad26.RSV.preF-based Vaccine, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more

Conditions: Hepatitis B, Chronic
Interventions: Entecavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 9
States / cities: San Francisco, California • Hartford, Connecticut • Gainesville, Florida + 6 more

Conditions: Acute Otitis Media, Ear Infection, Pediatric Infectious Disease
Interventions: Changes to the electronic health record (EHR), Individualized audit and feedback reporting for clinicians, Clinician education sessions, Use of a shared decision-making (SDM) aide, Shared decision-making (SDM) education; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 6 Months to 17 Years
Enrollment: 1,566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Murray, Utah

Conditions: HIV Infections, Tuberculosis
Interventions: Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Los Angeles, California • Torrance, California • Miami, Florida + 7 more

Conditions: Heart Failure, Gut Microbiome, Nutritional Deficiency
Interventions: Ensure Surgery Immunonutrition shake; Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Hiv, Adolescent Behavior, Family Relations, Sexual Orientation
Interventions: MySTYLE, Waitlist Control; Behavioral · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 14 Years to 20 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: HIV Infections
Interventions: Questionnaire; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lassa Fever
Interventions: ARN-75039 high, Intravenous ribavirin, ARN-75039 low; Drug
Lead sponsor: Arisan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Acute HIV Infection, HIV Infections
Interventions: Darunavir, Ritonavir, Etravirine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Search by objective public record fields.

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Hospital Avoidance Strategies for ABSSSI

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Use of a Rapid Test for Gonorrhea & Chlamydia for Women Presenting With Possible Sexually Transmitted Infections

Acupuncture and Post-Surgical Wound Healing

Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use

COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)

Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters

AO Multicenter Intervention Trial for Prevention of Surgical Site Infection

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection

Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

Enhanced Nutritional Optimization in LVAD Trial

MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South

An Observational Study of People Who Have Recently Been Infected With HIV

ARN-75039 Lassa Fever Treatment in West Africa

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine